X4 Pharmaceuticals (XFOR) Set to Announce Quarterly Earnings on Wednesday

X4 Pharmaceuticals (NASDAQ:XFOR) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect X4 Pharmaceuticals to announce earnings of ($0.1820) per share and revenue of $2.30 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. The firm had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million. On average, analysts expect X4 Pharmaceuticals to post ($0.67) EPS for the current fiscal year and ($0.73) EPS for the next fiscal year.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $3.25 on Wednesday. X4 Pharmaceuticals has a fifty-two week low of $2.43 and a fifty-two week high of $4.83. The stock has a fifty day moving average of $3.37 and a two-hundred day moving average of $3.81.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on XFOR. Wells Fargo & Company started coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an “overweight” rating and a $11.00 target price on the stock. Weiss Ratings lowered shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 20th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam Craig sold 47,436 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman owned 328,651 shares in the company, valued at $1,459,210.44. This represents a 12.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David Kirske sold 11,767 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total transaction of $33,653.62. Following the completion of the sale, the chief financial officer directly owned 155,983 shares of the company’s stock, valued at $446,111.38. This trade represents a 7.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 83,779 shares of company stock worth $353,387. 1.13% of the stock is currently owned by company insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.